Global RNA-based Therapeutics Drug Market 2023 by Company, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global RNA-based Therapeutics Drug market size was valued at USD 65800 million in 2022 and is forecast to a readjusted size of USD 84010 million by 2029 with a CAGR of 3.6% during review period.
Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes.
The Nucleic Acid-Based Therapeutics Drug Market is driven by the promising potential of nucleic acid-based therapies in treating various genetic and acquired diseases, including genetic disorders, cancer, and infectious diseases. These innovative drugs utilize nucleic acids, such as DNA or RNA, to modify or regulate gene expression, correct genetic mutations, or target specific disease-associated genes. As the understanding of genomics and molecular biology advances, and personalized medicine gains traction, the demand for nucleic acid-based therapeutics continues to grow. Innovations in drug development, delivery systems, and gene editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to address delivery and stability issues, ensure long-term safety and efficacy, and navigate regulatory complexities and patient acceptance. Overcoming technical and scientific hurdles, optimizing drug delivery methods, and addressing concerns about off-target effects are ongoing challenges. Additionally, the market faces competition from conventional therapies and the need for continuous research and development to unlock the full therapeutic potential of nucleic acid-based drugs. Striking a balance between providing safe, effective, and accessible nucleic acid-based therapeutics while addressing scientific and regulatory challenges is essential for the continued growth of the Nucleic Acid-Based Therapeutics Drug Market.
The Global Info Research report includes an overview of the development of the RNA-based Therapeutics Drug industry chain, the market status of Neuromuscular Diseases (Antisense Oligonucleotides (ASO), siRNA), hATTR (Antisense Oligonucleotides (ASO), siRNA), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of RNA-based Therapeutics Drug.
Regionally, the report analyzes the RNA-based Therapeutics Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global RNA-based Therapeutics Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the RNA-based Therapeutics Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the RNA-based Therapeutics Drug industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Antisense Oligonucleotides (ASO), siRNA).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the RNA-based Therapeutics Drug market.
Regional Analysis: The report involves examining the RNA-based Therapeutics Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the RNA-based Therapeutics Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to RNA-based Therapeutics Drug:
Company Analysis: Report covers individual RNA-based Therapeutics Drug players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards RNA-based Therapeutics Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Neuromuscular Diseases, hATTR).
Technology Analysis: Report covers specific technologies relevant to RNA-based Therapeutics Drug. It assesses the current state, advancements, and potential future developments in RNA-based Therapeutics Drug areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the RNA-based Therapeutics Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
RNA-based Therapeutics Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chapter 1, to describe RNA-based Therapeutics Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of RNA-based Therapeutics Drug, with revenue, gross margin and global market share of RNA-based Therapeutics Drug from 2018 to 2023.
Chapter 3, the RNA-based Therapeutics Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and RNA-based Therapeutics Drug market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of RNA-based Therapeutics Drug.
Chapter 13, to describe RNA-based Therapeutics Drug research findings and conclusion.
Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes.
The Nucleic Acid-Based Therapeutics Drug Market is driven by the promising potential of nucleic acid-based therapies in treating various genetic and acquired diseases, including genetic disorders, cancer, and infectious diseases. These innovative drugs utilize nucleic acids, such as DNA or RNA, to modify or regulate gene expression, correct genetic mutations, or target specific disease-associated genes. As the understanding of genomics and molecular biology advances, and personalized medicine gains traction, the demand for nucleic acid-based therapeutics continues to grow. Innovations in drug development, delivery systems, and gene editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to address delivery and stability issues, ensure long-term safety and efficacy, and navigate regulatory complexities and patient acceptance. Overcoming technical and scientific hurdles, optimizing drug delivery methods, and addressing concerns about off-target effects are ongoing challenges. Additionally, the market faces competition from conventional therapies and the need for continuous research and development to unlock the full therapeutic potential of nucleic acid-based drugs. Striking a balance between providing safe, effective, and accessible nucleic acid-based therapeutics while addressing scientific and regulatory challenges is essential for the continued growth of the Nucleic Acid-Based Therapeutics Drug Market.
The Global Info Research report includes an overview of the development of the RNA-based Therapeutics Drug industry chain, the market status of Neuromuscular Diseases (Antisense Oligonucleotides (ASO), siRNA), hATTR (Antisense Oligonucleotides (ASO), siRNA), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of RNA-based Therapeutics Drug.
Regionally, the report analyzes the RNA-based Therapeutics Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global RNA-based Therapeutics Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the RNA-based Therapeutics Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the RNA-based Therapeutics Drug industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Antisense Oligonucleotides (ASO), siRNA).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the RNA-based Therapeutics Drug market.
Regional Analysis: The report involves examining the RNA-based Therapeutics Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the RNA-based Therapeutics Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to RNA-based Therapeutics Drug:
Company Analysis: Report covers individual RNA-based Therapeutics Drug players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards RNA-based Therapeutics Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Neuromuscular Diseases, hATTR).
Technology Analysis: Report covers specific technologies relevant to RNA-based Therapeutics Drug. It assesses the current state, advancements, and potential future developments in RNA-based Therapeutics Drug areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the RNA-based Therapeutics Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
RNA-based Therapeutics Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- Antisense Oligonucleotides (ASO)
- siRNA
- mRNA
- Neuromuscular Diseases
- hATTR
- COVID-19
- Other
- Sarepta Therapeutics
- Ionis Pharmaceuticals
- Alnylam
- Biogen
- Nippon Shinyaku
- Sobi
- Novartis
- BioNTech
- Pfizer
- Moderna Therapeutics
- Jazz Pharmaceuticals
- CureVac
- Regulus Therapeutics
- ProQR
- Secarna
- MiNA Therapeutics
- Sylentis
- Arrowhead
- Silence Therapeutics
- Dicerna
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe RNA-based Therapeutics Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of RNA-based Therapeutics Drug, with revenue, gross margin and global market share of RNA-based Therapeutics Drug from 2018 to 2023.
Chapter 3, the RNA-based Therapeutics Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and RNA-based Therapeutics Drug market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of RNA-based Therapeutics Drug.
Chapter 13, to describe RNA-based Therapeutics Drug research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of RNA-based Therapeutics Drug
1.2 Market Estimation Caveats and Base Year
1.3 Classification of RNA-based Therapeutics Drug by Type
1.3.1 Overview: Global RNA-based Therapeutics Drug Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global RNA-based Therapeutics Drug Consumption Value Market Share by Type in 2022
1.3.3 Antisense Oligonucleotides (ASO)
1.3.4 siRNA
1.3.5 mRNA
1.4 Global RNA-based Therapeutics Drug Market by Application
1.4.1 Overview: Global RNA-based Therapeutics Drug Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Neuromuscular Diseases
1.4.3 hATTR
1.4.4 COVID-19
1.4.5 Other
1.5 Global RNA-based Therapeutics Drug Market Size & Forecast
1.6 Global RNA-based Therapeutics Drug Market Size and Forecast by Region
1.6.1 Global RNA-based Therapeutics Drug Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global RNA-based Therapeutics Drug Market Size by Region, (2018-2029)
1.6.3 North America RNA-based Therapeutics Drug Market Size and Prospect (2018-2029)
1.6.4 Europe RNA-based Therapeutics Drug Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific RNA-based Therapeutics Drug Market Size and Prospect (2018-2029)
1.6.6 South America RNA-based Therapeutics Drug Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa RNA-based Therapeutics Drug Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Sarepta Therapeutics
2.1.1 Sarepta Therapeutics Details
2.1.2 Sarepta Therapeutics Major Business
2.1.3 Sarepta Therapeutics RNA-based Therapeutics Drug Product and Solutions
2.1.4 Sarepta Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sarepta Therapeutics Recent Developments and Future Plans
2.2 Ionis Pharmaceuticals
2.2.1 Ionis Pharmaceuticals Details
2.2.2 Ionis Pharmaceuticals Major Business
2.2.3 Ionis Pharmaceuticals RNA-based Therapeutics Drug Product and Solutions
2.2.4 Ionis Pharmaceuticals RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Ionis Pharmaceuticals Recent Developments and Future Plans
2.3 Alnylam
2.3.1 Alnylam Details
2.3.2 Alnylam Major Business
2.3.3 Alnylam RNA-based Therapeutics Drug Product and Solutions
2.3.4 Alnylam RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Alnylam Recent Developments and Future Plans
2.4 Biogen
2.4.1 Biogen Details
2.4.2 Biogen Major Business
2.4.3 Biogen RNA-based Therapeutics Drug Product and Solutions
2.4.4 Biogen RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Biogen Recent Developments and Future Plans
2.5 Nippon Shinyaku
2.5.1 Nippon Shinyaku Details
2.5.2 Nippon Shinyaku Major Business
2.5.3 Nippon Shinyaku RNA-based Therapeutics Drug Product and Solutions
2.5.4 Nippon Shinyaku RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Nippon Shinyaku Recent Developments and Future Plans
2.6 Sobi
2.6.1 Sobi Details
2.6.2 Sobi Major Business
2.6.3 Sobi RNA-based Therapeutics Drug Product and Solutions
2.6.4 Sobi RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Sobi Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis RNA-based Therapeutics Drug Product and Solutions
2.7.4 Novartis RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Novartis Recent Developments and Future Plans
2.8 BioNTech
2.8.1 BioNTech Details
2.8.2 BioNTech Major Business
2.8.3 BioNTech RNA-based Therapeutics Drug Product and Solutions
2.8.4 BioNTech RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 BioNTech Recent Developments and Future Plans
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer RNA-based Therapeutics Drug Product and Solutions
2.9.4 Pfizer RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Pfizer Recent Developments and Future Plans
2.10 Moderna Therapeutics
2.10.1 Moderna Therapeutics Details
2.10.2 Moderna Therapeutics Major Business
2.10.3 Moderna Therapeutics RNA-based Therapeutics Drug Product and Solutions
2.10.4 Moderna Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Moderna Therapeutics Recent Developments and Future Plans
2.11 Jazz Pharmaceuticals
2.11.1 Jazz Pharmaceuticals Details
2.11.2 Jazz Pharmaceuticals Major Business
2.11.3 Jazz Pharmaceuticals RNA-based Therapeutics Drug Product and Solutions
2.11.4 Jazz Pharmaceuticals RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Jazz Pharmaceuticals Recent Developments and Future Plans
2.12 CureVac
2.12.1 CureVac Details
2.12.2 CureVac Major Business
2.12.3 CureVac RNA-based Therapeutics Drug Product and Solutions
2.12.4 CureVac RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 CureVac Recent Developments and Future Plans
2.13 Regulus Therapeutics
2.13.1 Regulus Therapeutics Details
2.13.2 Regulus Therapeutics Major Business
2.13.3 Regulus Therapeutics RNA-based Therapeutics Drug Product and Solutions
2.13.4 Regulus Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Regulus Therapeutics Recent Developments and Future Plans
2.14 ProQR
2.14.1 ProQR Details
2.14.2 ProQR Major Business
2.14.3 ProQR RNA-based Therapeutics Drug Product and Solutions
2.14.4 ProQR RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 ProQR Recent Developments and Future Plans
2.15 Secarna
2.15.1 Secarna Details
2.15.2 Secarna Major Business
2.15.3 Secarna RNA-based Therapeutics Drug Product and Solutions
2.15.4 Secarna RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Secarna Recent Developments and Future Plans
2.16 MiNA Therapeutics
2.16.1 MiNA Therapeutics Details
2.16.2 MiNA Therapeutics Major Business
2.16.3 MiNA Therapeutics RNA-based Therapeutics Drug Product and Solutions
2.16.4 MiNA Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 MiNA Therapeutics Recent Developments and Future Plans
2.17 Sylentis
2.17.1 Sylentis Details
2.17.2 Sylentis Major Business
2.17.3 Sylentis RNA-based Therapeutics Drug Product and Solutions
2.17.4 Sylentis RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Sylentis Recent Developments and Future Plans
2.18 Arrowhead
2.18.1 Arrowhead Details
2.18.2 Arrowhead Major Business
2.18.3 Arrowhead RNA-based Therapeutics Drug Product and Solutions
2.18.4 Arrowhead RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Arrowhead Recent Developments and Future Plans
2.19 Silence Therapeutics
2.19.1 Silence Therapeutics Details
2.19.2 Silence Therapeutics Major Business
2.19.3 Silence Therapeutics RNA-based Therapeutics Drug Product and Solutions
2.19.4 Silence Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 Silence Therapeutics Recent Developments and Future Plans
2.20 Dicerna
2.20.1 Dicerna Details
2.20.2 Dicerna Major Business
2.20.3 Dicerna RNA-based Therapeutics Drug Product and Solutions
2.20.4 Dicerna RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 Dicerna Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global RNA-based Therapeutics Drug Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of RNA-based Therapeutics Drug by Company Revenue
3.2.2 Top 3 RNA-based Therapeutics Drug Players Market Share in 2022
3.2.3 Top 6 RNA-based Therapeutics Drug Players Market Share in 2022
3.3 RNA-based Therapeutics Drug Market: Overall Company Footprint Analysis
3.3.1 RNA-based Therapeutics Drug Market: Region Footprint
3.3.2 RNA-based Therapeutics Drug Market: Company Product Type Footprint
3.3.3 RNA-based Therapeutics Drug Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global RNA-based Therapeutics Drug Consumption Value and Market Share by Type (2018-2023)
4.2 Global RNA-based Therapeutics Drug Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global RNA-based Therapeutics Drug Consumption Value Market Share by Application (2018-2023)
5.2 Global RNA-based Therapeutics Drug Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America RNA-based Therapeutics Drug Consumption Value by Type (2018-2029)
6.2 North America RNA-based Therapeutics Drug Consumption Value by Application (2018-2029)
6.3 North America RNA-based Therapeutics Drug Market Size by Country
6.3.1 North America RNA-based Therapeutics Drug Consumption Value by Country (2018-2029)
6.3.2 United States RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
6.3.3 Canada RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
6.3.4 Mexico RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe RNA-based Therapeutics Drug Consumption Value by Type (2018-2029)
7.2 Europe RNA-based Therapeutics Drug Consumption Value by Application (2018-2029)
7.3 Europe RNA-based Therapeutics Drug Market Size by Country
7.3.1 Europe RNA-based Therapeutics Drug Consumption Value by Country (2018-2029)
7.3.2 Germany RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
7.3.3 France RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
7.3.4 United Kingdom RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
7.3.5 Russia RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
7.3.6 Italy RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Type (2018-2029)
8.2 Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Application (2018-2029)
8.3 Asia-Pacific RNA-based Therapeutics Drug Market Size by Region
8.3.1 Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Region (2018-2029)
8.3.2 China RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
8.3.3 Japan RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
8.3.4 South Korea RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
8.3.5 India RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
8.3.7 Australia RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America RNA-based Therapeutics Drug Consumption Value by Type (2018-2029)
9.2 South America RNA-based Therapeutics Drug Consumption Value by Application (2018-2029)
9.3 South America RNA-based Therapeutics Drug Market Size by Country
9.3.1 South America RNA-based Therapeutics Drug Consumption Value by Country (2018-2029)
9.3.2 Brazil RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
9.3.3 Argentina RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Type (2018-2029)
10.2 Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Application (2018-2029)
10.3 Middle East & Africa RNA-based Therapeutics Drug Market Size by Country
10.3.1 Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Country (2018-2029)
10.3.2 Turkey RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
10.3.4 UAE RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 RNA-based Therapeutics Drug Market Drivers
11.2 RNA-based Therapeutics Drug Market Restraints
11.3 RNA-based Therapeutics Drug Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 RNA-based Therapeutics Drug Industry Chain
12.2 RNA-based Therapeutics Drug Upstream Analysis
12.3 RNA-based Therapeutics Drug Midstream Analysis
12.4 RNA-based Therapeutics Drug Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of RNA-based Therapeutics Drug
1.2 Market Estimation Caveats and Base Year
1.3 Classification of RNA-based Therapeutics Drug by Type
1.3.1 Overview: Global RNA-based Therapeutics Drug Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global RNA-based Therapeutics Drug Consumption Value Market Share by Type in 2022
1.3.3 Antisense Oligonucleotides (ASO)
1.3.4 siRNA
1.3.5 mRNA
1.4 Global RNA-based Therapeutics Drug Market by Application
1.4.1 Overview: Global RNA-based Therapeutics Drug Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Neuromuscular Diseases
1.4.3 hATTR
1.4.4 COVID-19
1.4.5 Other
1.5 Global RNA-based Therapeutics Drug Market Size & Forecast
1.6 Global RNA-based Therapeutics Drug Market Size and Forecast by Region
1.6.1 Global RNA-based Therapeutics Drug Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global RNA-based Therapeutics Drug Market Size by Region, (2018-2029)
1.6.3 North America RNA-based Therapeutics Drug Market Size and Prospect (2018-2029)
1.6.4 Europe RNA-based Therapeutics Drug Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific RNA-based Therapeutics Drug Market Size and Prospect (2018-2029)
1.6.6 South America RNA-based Therapeutics Drug Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa RNA-based Therapeutics Drug Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Sarepta Therapeutics
2.1.1 Sarepta Therapeutics Details
2.1.2 Sarepta Therapeutics Major Business
2.1.3 Sarepta Therapeutics RNA-based Therapeutics Drug Product and Solutions
2.1.4 Sarepta Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sarepta Therapeutics Recent Developments and Future Plans
2.2 Ionis Pharmaceuticals
2.2.1 Ionis Pharmaceuticals Details
2.2.2 Ionis Pharmaceuticals Major Business
2.2.3 Ionis Pharmaceuticals RNA-based Therapeutics Drug Product and Solutions
2.2.4 Ionis Pharmaceuticals RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Ionis Pharmaceuticals Recent Developments and Future Plans
2.3 Alnylam
2.3.1 Alnylam Details
2.3.2 Alnylam Major Business
2.3.3 Alnylam RNA-based Therapeutics Drug Product and Solutions
2.3.4 Alnylam RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Alnylam Recent Developments and Future Plans
2.4 Biogen
2.4.1 Biogen Details
2.4.2 Biogen Major Business
2.4.3 Biogen RNA-based Therapeutics Drug Product and Solutions
2.4.4 Biogen RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Biogen Recent Developments and Future Plans
2.5 Nippon Shinyaku
2.5.1 Nippon Shinyaku Details
2.5.2 Nippon Shinyaku Major Business
2.5.3 Nippon Shinyaku RNA-based Therapeutics Drug Product and Solutions
2.5.4 Nippon Shinyaku RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Nippon Shinyaku Recent Developments and Future Plans
2.6 Sobi
2.6.1 Sobi Details
2.6.2 Sobi Major Business
2.6.3 Sobi RNA-based Therapeutics Drug Product and Solutions
2.6.4 Sobi RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Sobi Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis RNA-based Therapeutics Drug Product and Solutions
2.7.4 Novartis RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Novartis Recent Developments and Future Plans
2.8 BioNTech
2.8.1 BioNTech Details
2.8.2 BioNTech Major Business
2.8.3 BioNTech RNA-based Therapeutics Drug Product and Solutions
2.8.4 BioNTech RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 BioNTech Recent Developments and Future Plans
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer RNA-based Therapeutics Drug Product and Solutions
2.9.4 Pfizer RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Pfizer Recent Developments and Future Plans
2.10 Moderna Therapeutics
2.10.1 Moderna Therapeutics Details
2.10.2 Moderna Therapeutics Major Business
2.10.3 Moderna Therapeutics RNA-based Therapeutics Drug Product and Solutions
2.10.4 Moderna Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Moderna Therapeutics Recent Developments and Future Plans
2.11 Jazz Pharmaceuticals
2.11.1 Jazz Pharmaceuticals Details
2.11.2 Jazz Pharmaceuticals Major Business
2.11.3 Jazz Pharmaceuticals RNA-based Therapeutics Drug Product and Solutions
2.11.4 Jazz Pharmaceuticals RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Jazz Pharmaceuticals Recent Developments and Future Plans
2.12 CureVac
2.12.1 CureVac Details
2.12.2 CureVac Major Business
2.12.3 CureVac RNA-based Therapeutics Drug Product and Solutions
2.12.4 CureVac RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 CureVac Recent Developments and Future Plans
2.13 Regulus Therapeutics
2.13.1 Regulus Therapeutics Details
2.13.2 Regulus Therapeutics Major Business
2.13.3 Regulus Therapeutics RNA-based Therapeutics Drug Product and Solutions
2.13.4 Regulus Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Regulus Therapeutics Recent Developments and Future Plans
2.14 ProQR
2.14.1 ProQR Details
2.14.2 ProQR Major Business
2.14.3 ProQR RNA-based Therapeutics Drug Product and Solutions
2.14.4 ProQR RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 ProQR Recent Developments and Future Plans
2.15 Secarna
2.15.1 Secarna Details
2.15.2 Secarna Major Business
2.15.3 Secarna RNA-based Therapeutics Drug Product and Solutions
2.15.4 Secarna RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Secarna Recent Developments and Future Plans
2.16 MiNA Therapeutics
2.16.1 MiNA Therapeutics Details
2.16.2 MiNA Therapeutics Major Business
2.16.3 MiNA Therapeutics RNA-based Therapeutics Drug Product and Solutions
2.16.4 MiNA Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 MiNA Therapeutics Recent Developments and Future Plans
2.17 Sylentis
2.17.1 Sylentis Details
2.17.2 Sylentis Major Business
2.17.3 Sylentis RNA-based Therapeutics Drug Product and Solutions
2.17.4 Sylentis RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Sylentis Recent Developments and Future Plans
2.18 Arrowhead
2.18.1 Arrowhead Details
2.18.2 Arrowhead Major Business
2.18.3 Arrowhead RNA-based Therapeutics Drug Product and Solutions
2.18.4 Arrowhead RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Arrowhead Recent Developments and Future Plans
2.19 Silence Therapeutics
2.19.1 Silence Therapeutics Details
2.19.2 Silence Therapeutics Major Business
2.19.3 Silence Therapeutics RNA-based Therapeutics Drug Product and Solutions
2.19.4 Silence Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 Silence Therapeutics Recent Developments and Future Plans
2.20 Dicerna
2.20.1 Dicerna Details
2.20.2 Dicerna Major Business
2.20.3 Dicerna RNA-based Therapeutics Drug Product and Solutions
2.20.4 Dicerna RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 Dicerna Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global RNA-based Therapeutics Drug Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of RNA-based Therapeutics Drug by Company Revenue
3.2.2 Top 3 RNA-based Therapeutics Drug Players Market Share in 2022
3.2.3 Top 6 RNA-based Therapeutics Drug Players Market Share in 2022
3.3 RNA-based Therapeutics Drug Market: Overall Company Footprint Analysis
3.3.1 RNA-based Therapeutics Drug Market: Region Footprint
3.3.2 RNA-based Therapeutics Drug Market: Company Product Type Footprint
3.3.3 RNA-based Therapeutics Drug Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global RNA-based Therapeutics Drug Consumption Value and Market Share by Type (2018-2023)
4.2 Global RNA-based Therapeutics Drug Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global RNA-based Therapeutics Drug Consumption Value Market Share by Application (2018-2023)
5.2 Global RNA-based Therapeutics Drug Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America RNA-based Therapeutics Drug Consumption Value by Type (2018-2029)
6.2 North America RNA-based Therapeutics Drug Consumption Value by Application (2018-2029)
6.3 North America RNA-based Therapeutics Drug Market Size by Country
6.3.1 North America RNA-based Therapeutics Drug Consumption Value by Country (2018-2029)
6.3.2 United States RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
6.3.3 Canada RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
6.3.4 Mexico RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe RNA-based Therapeutics Drug Consumption Value by Type (2018-2029)
7.2 Europe RNA-based Therapeutics Drug Consumption Value by Application (2018-2029)
7.3 Europe RNA-based Therapeutics Drug Market Size by Country
7.3.1 Europe RNA-based Therapeutics Drug Consumption Value by Country (2018-2029)
7.3.2 Germany RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
7.3.3 France RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
7.3.4 United Kingdom RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
7.3.5 Russia RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
7.3.6 Italy RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Type (2018-2029)
8.2 Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Application (2018-2029)
8.3 Asia-Pacific RNA-based Therapeutics Drug Market Size by Region
8.3.1 Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Region (2018-2029)
8.3.2 China RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
8.3.3 Japan RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
8.3.4 South Korea RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
8.3.5 India RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
8.3.7 Australia RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America RNA-based Therapeutics Drug Consumption Value by Type (2018-2029)
9.2 South America RNA-based Therapeutics Drug Consumption Value by Application (2018-2029)
9.3 South America RNA-based Therapeutics Drug Market Size by Country
9.3.1 South America RNA-based Therapeutics Drug Consumption Value by Country (2018-2029)
9.3.2 Brazil RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
9.3.3 Argentina RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Type (2018-2029)
10.2 Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Application (2018-2029)
10.3 Middle East & Africa RNA-based Therapeutics Drug Market Size by Country
10.3.1 Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Country (2018-2029)
10.3.2 Turkey RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
10.3.4 UAE RNA-based Therapeutics Drug Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 RNA-based Therapeutics Drug Market Drivers
11.2 RNA-based Therapeutics Drug Market Restraints
11.3 RNA-based Therapeutics Drug Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 RNA-based Therapeutics Drug Industry Chain
12.2 RNA-based Therapeutics Drug Upstream Analysis
12.3 RNA-based Therapeutics Drug Midstream Analysis
12.4 RNA-based Therapeutics Drug Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global RNA-based Therapeutics Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global RNA-based Therapeutics Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global RNA-based Therapeutics Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global RNA-based Therapeutics Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
Table 6. Sarepta Therapeutics Major Business
Table 7. Sarepta Therapeutics RNA-based Therapeutics Drug Product and Solutions
Table 8. Sarepta Therapeutics RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Sarepta Therapeutics Recent Developments and Future Plans
Table 10. Ionis Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 11. Ionis Pharmaceuticals Major Business
Table 12. Ionis Pharmaceuticals RNA-based Therapeutics Drug Product and Solutions
Table 13. Ionis Pharmaceuticals RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Ionis Pharmaceuticals Recent Developments and Future Plans
Table 15. Alnylam Company Information, Head Office, and Major Competitors
Table 16. Alnylam Major Business
Table 17. Alnylam RNA-based Therapeutics Drug Product and Solutions
Table 18. Alnylam RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Alnylam Recent Developments and Future Plans
Table 20. Biogen Company Information, Head Office, and Major Competitors
Table 21. Biogen Major Business
Table 22. Biogen RNA-based Therapeutics Drug Product and Solutions
Table 23. Biogen RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Biogen Recent Developments and Future Plans
Table 25. Nippon Shinyaku Company Information, Head Office, and Major Competitors
Table 26. Nippon Shinyaku Major Business
Table 27. Nippon Shinyaku RNA-based Therapeutics Drug Product and Solutions
Table 28. Nippon Shinyaku RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Nippon Shinyaku Recent Developments and Future Plans
Table 30. Sobi Company Information, Head Office, and Major Competitors
Table 31. Sobi Major Business
Table 32. Sobi RNA-based Therapeutics Drug Product and Solutions
Table 33. Sobi RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Sobi Recent Developments and Future Plans
Table 35. Novartis Company Information, Head Office, and Major Competitors
Table 36. Novartis Major Business
Table 37. Novartis RNA-based Therapeutics Drug Product and Solutions
Table 38. Novartis RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Novartis Recent Developments and Future Plans
Table 40. BioNTech Company Information, Head Office, and Major Competitors
Table 41. BioNTech Major Business
Table 42. BioNTech RNA-based Therapeutics Drug Product and Solutions
Table 43. BioNTech RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. BioNTech Recent Developments and Future Plans
Table 45. Pfizer Company Information, Head Office, and Major Competitors
Table 46. Pfizer Major Business
Table 47. Pfizer RNA-based Therapeutics Drug Product and Solutions
Table 48. Pfizer RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Pfizer Recent Developments and Future Plans
Table 50. Moderna Therapeutics Company Information, Head Office, and Major Competitors
Table 51. Moderna Therapeutics Major Business
Table 52. Moderna Therapeutics RNA-based Therapeutics Drug Product and Solutions
Table 53. Moderna Therapeutics RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Moderna Therapeutics Recent Developments and Future Plans
Table 55. Jazz Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 56. Jazz Pharmaceuticals Major Business
Table 57. Jazz Pharmaceuticals RNA-based Therapeutics Drug Product and Solutions
Table 58. Jazz Pharmaceuticals RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Jazz Pharmaceuticals Recent Developments and Future Plans
Table 60. CureVac Company Information, Head Office, and Major Competitors
Table 61. CureVac Major Business
Table 62. CureVac RNA-based Therapeutics Drug Product and Solutions
Table 63. CureVac RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. CureVac Recent Developments and Future Plans
Table 65. Regulus Therapeutics Company Information, Head Office, and Major Competitors
Table 66. Regulus Therapeutics Major Business
Table 67. Regulus Therapeutics RNA-based Therapeutics Drug Product and Solutions
Table 68. Regulus Therapeutics RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Regulus Therapeutics Recent Developments and Future Plans
Table 70. ProQR Company Information, Head Office, and Major Competitors
Table 71. ProQR Major Business
Table 72. ProQR RNA-based Therapeutics Drug Product and Solutions
Table 73. ProQR RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. ProQR Recent Developments and Future Plans
Table 75. Secarna Company Information, Head Office, and Major Competitors
Table 76. Secarna Major Business
Table 77. Secarna RNA-based Therapeutics Drug Product and Solutions
Table 78. Secarna RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Secarna Recent Developments and Future Plans
Table 80. MiNA Therapeutics Company Information, Head Office, and Major Competitors
Table 81. MiNA Therapeutics Major Business
Table 82. MiNA Therapeutics RNA-based Therapeutics Drug Product and Solutions
Table 83. MiNA Therapeutics RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. MiNA Therapeutics Recent Developments and Future Plans
Table 85. Sylentis Company Information, Head Office, and Major Competitors
Table 86. Sylentis Major Business
Table 87. Sylentis RNA-based Therapeutics Drug Product and Solutions
Table 88. Sylentis RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Sylentis Recent Developments and Future Plans
Table 90. Arrowhead Company Information, Head Office, and Major Competitors
Table 91. Arrowhead Major Business
Table 92. Arrowhead RNA-based Therapeutics Drug Product and Solutions
Table 93. Arrowhead RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 94. Arrowhead Recent Developments and Future Plans
Table 95. Silence Therapeutics Company Information, Head Office, and Major Competitors
Table 96. Silence Therapeutics Major Business
Table 97. Silence Therapeutics RNA-based Therapeutics Drug Product and Solutions
Table 98. Silence Therapeutics RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 99. Silence Therapeutics Recent Developments and Future Plans
Table 100. Dicerna Company Information, Head Office, and Major Competitors
Table 101. Dicerna Major Business
Table 102. Dicerna RNA-based Therapeutics Drug Product and Solutions
Table 103. Dicerna RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 104. Dicerna Recent Developments and Future Plans
Table 105. Global RNA-based Therapeutics Drug Revenue (USD Million) by Players (2018-2023)
Table 106. Global RNA-based Therapeutics Drug Revenue Share by Players (2018-2023)
Table 107. Breakdown of RNA-based Therapeutics Drug by Company Type (Tier 1, Tier 2, and Tier 3)
Table 108. Market Position of Players in RNA-based Therapeutics Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 109. Head Office of Key RNA-based Therapeutics Drug Players
Table 110. RNA-based Therapeutics Drug Market: Company Product Type Footprint
Table 111. RNA-based Therapeutics Drug Market: Company Product Application Footprint
Table 112. RNA-based Therapeutics Drug New Market Entrants and Barriers to Market Entry
Table 113. RNA-based Therapeutics Drug Mergers, Acquisition, Agreements, and Collaborations
Table 114. Global RNA-based Therapeutics Drug Consumption Value (USD Million) by Type (2018-2023)
Table 115. Global RNA-based Therapeutics Drug Consumption Value Share by Type (2018-2023)
Table 116. Global RNA-based Therapeutics Drug Consumption Value Forecast by Type (2024-2029)
Table 117. Global RNA-based Therapeutics Drug Consumption Value by Application (2018-2023)
Table 118. Global RNA-based Therapeutics Drug Consumption Value Forecast by Application (2024-2029)
Table 119. North America RNA-based Therapeutics Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 120. North America RNA-based Therapeutics Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 121. North America RNA-based Therapeutics Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 122. North America RNA-based Therapeutics Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 123. North America RNA-based Therapeutics Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 124. North America RNA-based Therapeutics Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 125. Europe RNA-based Therapeutics Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 126. Europe RNA-based Therapeutics Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 127. Europe RNA-based Therapeutics Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 128. Europe RNA-based Therapeutics Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 129. Europe RNA-based Therapeutics Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 130. Europe RNA-based Therapeutics Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 131. Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 132. Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 133. Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 134. Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 135. Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 136. Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 137. South America RNA-based Therapeutics Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 138. South America RNA-based Therapeutics Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 139. South America RNA-based Therapeutics Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 140. South America RNA-based Therapeutics Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 141. South America RNA-based Therapeutics Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 142. South America RNA-based Therapeutics Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 143. Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 144. Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 145. Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 146. Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 147. Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 148. Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 149. RNA-based Therapeutics Drug Raw Material
Table 150. Key Suppliers of RNA-based Therapeutics Drug Raw Materials
Table 1. Global RNA-based Therapeutics Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global RNA-based Therapeutics Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global RNA-based Therapeutics Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global RNA-based Therapeutics Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
Table 6. Sarepta Therapeutics Major Business
Table 7. Sarepta Therapeutics RNA-based Therapeutics Drug Product and Solutions
Table 8. Sarepta Therapeutics RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Sarepta Therapeutics Recent Developments and Future Plans
Table 10. Ionis Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 11. Ionis Pharmaceuticals Major Business
Table 12. Ionis Pharmaceuticals RNA-based Therapeutics Drug Product and Solutions
Table 13. Ionis Pharmaceuticals RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Ionis Pharmaceuticals Recent Developments and Future Plans
Table 15. Alnylam Company Information, Head Office, and Major Competitors
Table 16. Alnylam Major Business
Table 17. Alnylam RNA-based Therapeutics Drug Product and Solutions
Table 18. Alnylam RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Alnylam Recent Developments and Future Plans
Table 20. Biogen Company Information, Head Office, and Major Competitors
Table 21. Biogen Major Business
Table 22. Biogen RNA-based Therapeutics Drug Product and Solutions
Table 23. Biogen RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Biogen Recent Developments and Future Plans
Table 25. Nippon Shinyaku Company Information, Head Office, and Major Competitors
Table 26. Nippon Shinyaku Major Business
Table 27. Nippon Shinyaku RNA-based Therapeutics Drug Product and Solutions
Table 28. Nippon Shinyaku RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Nippon Shinyaku Recent Developments and Future Plans
Table 30. Sobi Company Information, Head Office, and Major Competitors
Table 31. Sobi Major Business
Table 32. Sobi RNA-based Therapeutics Drug Product and Solutions
Table 33. Sobi RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Sobi Recent Developments and Future Plans
Table 35. Novartis Company Information, Head Office, and Major Competitors
Table 36. Novartis Major Business
Table 37. Novartis RNA-based Therapeutics Drug Product and Solutions
Table 38. Novartis RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Novartis Recent Developments and Future Plans
Table 40. BioNTech Company Information, Head Office, and Major Competitors
Table 41. BioNTech Major Business
Table 42. BioNTech RNA-based Therapeutics Drug Product and Solutions
Table 43. BioNTech RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. BioNTech Recent Developments and Future Plans
Table 45. Pfizer Company Information, Head Office, and Major Competitors
Table 46. Pfizer Major Business
Table 47. Pfizer RNA-based Therapeutics Drug Product and Solutions
Table 48. Pfizer RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Pfizer Recent Developments and Future Plans
Table 50. Moderna Therapeutics Company Information, Head Office, and Major Competitors
Table 51. Moderna Therapeutics Major Business
Table 52. Moderna Therapeutics RNA-based Therapeutics Drug Product and Solutions
Table 53. Moderna Therapeutics RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Moderna Therapeutics Recent Developments and Future Plans
Table 55. Jazz Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 56. Jazz Pharmaceuticals Major Business
Table 57. Jazz Pharmaceuticals RNA-based Therapeutics Drug Product and Solutions
Table 58. Jazz Pharmaceuticals RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Jazz Pharmaceuticals Recent Developments and Future Plans
Table 60. CureVac Company Information, Head Office, and Major Competitors
Table 61. CureVac Major Business
Table 62. CureVac RNA-based Therapeutics Drug Product and Solutions
Table 63. CureVac RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. CureVac Recent Developments and Future Plans
Table 65. Regulus Therapeutics Company Information, Head Office, and Major Competitors
Table 66. Regulus Therapeutics Major Business
Table 67. Regulus Therapeutics RNA-based Therapeutics Drug Product and Solutions
Table 68. Regulus Therapeutics RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Regulus Therapeutics Recent Developments and Future Plans
Table 70. ProQR Company Information, Head Office, and Major Competitors
Table 71. ProQR Major Business
Table 72. ProQR RNA-based Therapeutics Drug Product and Solutions
Table 73. ProQR RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. ProQR Recent Developments and Future Plans
Table 75. Secarna Company Information, Head Office, and Major Competitors
Table 76. Secarna Major Business
Table 77. Secarna RNA-based Therapeutics Drug Product and Solutions
Table 78. Secarna RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Secarna Recent Developments and Future Plans
Table 80. MiNA Therapeutics Company Information, Head Office, and Major Competitors
Table 81. MiNA Therapeutics Major Business
Table 82. MiNA Therapeutics RNA-based Therapeutics Drug Product and Solutions
Table 83. MiNA Therapeutics RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. MiNA Therapeutics Recent Developments and Future Plans
Table 85. Sylentis Company Information, Head Office, and Major Competitors
Table 86. Sylentis Major Business
Table 87. Sylentis RNA-based Therapeutics Drug Product and Solutions
Table 88. Sylentis RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Sylentis Recent Developments and Future Plans
Table 90. Arrowhead Company Information, Head Office, and Major Competitors
Table 91. Arrowhead Major Business
Table 92. Arrowhead RNA-based Therapeutics Drug Product and Solutions
Table 93. Arrowhead RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 94. Arrowhead Recent Developments and Future Plans
Table 95. Silence Therapeutics Company Information, Head Office, and Major Competitors
Table 96. Silence Therapeutics Major Business
Table 97. Silence Therapeutics RNA-based Therapeutics Drug Product and Solutions
Table 98. Silence Therapeutics RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 99. Silence Therapeutics Recent Developments and Future Plans
Table 100. Dicerna Company Information, Head Office, and Major Competitors
Table 101. Dicerna Major Business
Table 102. Dicerna RNA-based Therapeutics Drug Product and Solutions
Table 103. Dicerna RNA-based Therapeutics Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 104. Dicerna Recent Developments and Future Plans
Table 105. Global RNA-based Therapeutics Drug Revenue (USD Million) by Players (2018-2023)
Table 106. Global RNA-based Therapeutics Drug Revenue Share by Players (2018-2023)
Table 107. Breakdown of RNA-based Therapeutics Drug by Company Type (Tier 1, Tier 2, and Tier 3)
Table 108. Market Position of Players in RNA-based Therapeutics Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 109. Head Office of Key RNA-based Therapeutics Drug Players
Table 110. RNA-based Therapeutics Drug Market: Company Product Type Footprint
Table 111. RNA-based Therapeutics Drug Market: Company Product Application Footprint
Table 112. RNA-based Therapeutics Drug New Market Entrants and Barriers to Market Entry
Table 113. RNA-based Therapeutics Drug Mergers, Acquisition, Agreements, and Collaborations
Table 114. Global RNA-based Therapeutics Drug Consumption Value (USD Million) by Type (2018-2023)
Table 115. Global RNA-based Therapeutics Drug Consumption Value Share by Type (2018-2023)
Table 116. Global RNA-based Therapeutics Drug Consumption Value Forecast by Type (2024-2029)
Table 117. Global RNA-based Therapeutics Drug Consumption Value by Application (2018-2023)
Table 118. Global RNA-based Therapeutics Drug Consumption Value Forecast by Application (2024-2029)
Table 119. North America RNA-based Therapeutics Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 120. North America RNA-based Therapeutics Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 121. North America RNA-based Therapeutics Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 122. North America RNA-based Therapeutics Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 123. North America RNA-based Therapeutics Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 124. North America RNA-based Therapeutics Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 125. Europe RNA-based Therapeutics Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 126. Europe RNA-based Therapeutics Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 127. Europe RNA-based Therapeutics Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 128. Europe RNA-based Therapeutics Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 129. Europe RNA-based Therapeutics Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 130. Europe RNA-based Therapeutics Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 131. Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 132. Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 133. Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 134. Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 135. Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 136. Asia-Pacific RNA-based Therapeutics Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 137. South America RNA-based Therapeutics Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 138. South America RNA-based Therapeutics Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 139. South America RNA-based Therapeutics Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 140. South America RNA-based Therapeutics Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 141. South America RNA-based Therapeutics Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 142. South America RNA-based Therapeutics Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 143. Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 144. Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 145. Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 146. Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 147. Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 148. Middle East & Africa RNA-based Therapeutics Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 149. RNA-based Therapeutics Drug Raw Material
Table 150. Key Suppliers of RNA-based Therapeutics Drug Raw Materials
LIST OF FIGURES
Figure 1. RNA-based Therapeutics Drug Picture
Figure 2. Global RNA-based Therapeutics Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global RNA-based Therapeutics Drug Consumption Value Market Share by Type in 2022
Figure 4. Antisense Oligonucleotides (ASO)
Figure 5. siRNA
Figure 6. mRNA
Figure 7. Global RNA-based Therapeutics Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 8. RNA-based Therapeutics Drug Consumption Value Market Share by Application in 2022
Figure 9. Neuromuscular Diseases Picture
Figure 10. hATTR Picture
Figure 11. COVID-19 Picture
Figure 12. Other Picture
Figure 13. Global RNA-based Therapeutics Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global RNA-based Therapeutics Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market RNA-based Therapeutics Drug Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global RNA-based Therapeutics Drug Consumption Value Market Share by Region (2018-2029)
Figure 17. Global RNA-based Therapeutics Drug Consumption Value Market Share by Region in 2022
Figure 18. North America RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 21. South America RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 23. Global RNA-based Therapeutics Drug Revenue Share by Players in 2022
Figure 24. RNA-based Therapeutics Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players RNA-based Therapeutics Drug Market Share in 2022
Figure 26. Global Top 6 Players RNA-based Therapeutics Drug Market Share in 2022
Figure 27. Global RNA-based Therapeutics Drug Consumption Value Share by Type (2018-2023)
Figure 28. Global RNA-based Therapeutics Drug Market Share Forecast by Type (2024-2029)
Figure 29. Global RNA-based Therapeutics Drug Consumption Value Share by Application (2018-2023)
Figure 30. Global RNA-based Therapeutics Drug Market Share Forecast by Application (2024-2029)
Figure 31. North America RNA-based Therapeutics Drug Consumption Value Market Share by Type (2018-2029)
Figure 32. North America RNA-based Therapeutics Drug Consumption Value Market Share by Application (2018-2029)
Figure 33. North America RNA-based Therapeutics Drug Consumption Value Market Share by Country (2018-2029)
Figure 34. United States RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe RNA-based Therapeutics Drug Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe RNA-based Therapeutics Drug Consumption Value Market Share by Application (2018-2029)
Figure 39. Europe RNA-based Therapeutics Drug Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 41. France RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific RNA-based Therapeutics Drug Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific RNA-based Therapeutics Drug Consumption Value Market Share by Application (2018-2029)
Figure 47. Asia-Pacific RNA-based Therapeutics Drug Consumption Value Market Share by Region (2018-2029)
Figure 48. China RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 51. India RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 54. South America RNA-based Therapeutics Drug Consumption Value Market Share by Type (2018-2029)
Figure 55. South America RNA-based Therapeutics Drug Consumption Value Market Share by Application (2018-2029)
Figure 56. South America RNA-based Therapeutics Drug Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa RNA-based Therapeutics Drug Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa RNA-based Therapeutics Drug Consumption Value Market Share by Application (2018-2029)
Figure 61. Middle East and Africa RNA-based Therapeutics Drug Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 65. RNA-based Therapeutics Drug Market Drivers
Figure 66. RNA-based Therapeutics Drug Market Restraints
Figure 67. RNA-based Therapeutics Drug Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of RNA-based Therapeutics Drug in 2022
Figure 70. Manufacturing Process Analysis of RNA-based Therapeutics Drug
Figure 71. RNA-based Therapeutics Drug Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
Figure 1. RNA-based Therapeutics Drug Picture
Figure 2. Global RNA-based Therapeutics Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global RNA-based Therapeutics Drug Consumption Value Market Share by Type in 2022
Figure 4. Antisense Oligonucleotides (ASO)
Figure 5. siRNA
Figure 6. mRNA
Figure 7. Global RNA-based Therapeutics Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 8. RNA-based Therapeutics Drug Consumption Value Market Share by Application in 2022
Figure 9. Neuromuscular Diseases Picture
Figure 10. hATTR Picture
Figure 11. COVID-19 Picture
Figure 12. Other Picture
Figure 13. Global RNA-based Therapeutics Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global RNA-based Therapeutics Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market RNA-based Therapeutics Drug Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global RNA-based Therapeutics Drug Consumption Value Market Share by Region (2018-2029)
Figure 17. Global RNA-based Therapeutics Drug Consumption Value Market Share by Region in 2022
Figure 18. North America RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 21. South America RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 23. Global RNA-based Therapeutics Drug Revenue Share by Players in 2022
Figure 24. RNA-based Therapeutics Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players RNA-based Therapeutics Drug Market Share in 2022
Figure 26. Global Top 6 Players RNA-based Therapeutics Drug Market Share in 2022
Figure 27. Global RNA-based Therapeutics Drug Consumption Value Share by Type (2018-2023)
Figure 28. Global RNA-based Therapeutics Drug Market Share Forecast by Type (2024-2029)
Figure 29. Global RNA-based Therapeutics Drug Consumption Value Share by Application (2018-2023)
Figure 30. Global RNA-based Therapeutics Drug Market Share Forecast by Application (2024-2029)
Figure 31. North America RNA-based Therapeutics Drug Consumption Value Market Share by Type (2018-2029)
Figure 32. North America RNA-based Therapeutics Drug Consumption Value Market Share by Application (2018-2029)
Figure 33. North America RNA-based Therapeutics Drug Consumption Value Market Share by Country (2018-2029)
Figure 34. United States RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe RNA-based Therapeutics Drug Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe RNA-based Therapeutics Drug Consumption Value Market Share by Application (2018-2029)
Figure 39. Europe RNA-based Therapeutics Drug Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 41. France RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific RNA-based Therapeutics Drug Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific RNA-based Therapeutics Drug Consumption Value Market Share by Application (2018-2029)
Figure 47. Asia-Pacific RNA-based Therapeutics Drug Consumption Value Market Share by Region (2018-2029)
Figure 48. China RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 51. India RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 54. South America RNA-based Therapeutics Drug Consumption Value Market Share by Type (2018-2029)
Figure 55. South America RNA-based Therapeutics Drug Consumption Value Market Share by Application (2018-2029)
Figure 56. South America RNA-based Therapeutics Drug Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa RNA-based Therapeutics Drug Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa RNA-based Therapeutics Drug Consumption Value Market Share by Application (2018-2029)
Figure 61. Middle East and Africa RNA-based Therapeutics Drug Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE RNA-based Therapeutics Drug Consumption Value (2018-2029) & (USD Million)
Figure 65. RNA-based Therapeutics Drug Market Drivers
Figure 66. RNA-based Therapeutics Drug Market Restraints
Figure 67. RNA-based Therapeutics Drug Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of RNA-based Therapeutics Drug in 2022
Figure 70. Manufacturing Process Analysis of RNA-based Therapeutics Drug
Figure 71. RNA-based Therapeutics Drug Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
